Pharmacoeconomics of the new antidepressants and antipsychotics;Pharmakoökonomie von antidepressiva und antipsychotika

Psychiatrische Praxis, Supplement

Volumn 30, Issue 2, 2003, Pages

  Laux, Gerd ^a  

^a Bezirksklinikum Gabersee   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUPENTIXOL; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLANT EXTRACT; PSYCHOTROPIC AGENT; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

CLINICAL TRIAL; CONFERENCE PAPER; COST UTILITY ANALYSIS; DEPRESSION; DRUG COST; HUMAN; META ANALYSIS; METHODOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; SIMULATION;

EID: 0038451523     PISSN: 16118332     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17: 383-389
2. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997; 17: 298-307
3. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000; 57: 987-994
4. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998; 14: 97-133
5. Foster RH, Goa KL. Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999; 15: 611-640
6. Hamilton SH, Revicki DA, Edgell ET et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics 1999; 15: 469-480
7. Jones MT, Cockrum PC. A critical review of published economic modelling studies in depression. Pharmacoeconomics 2000; 17: 555-583
8. Kissling W, Hoffler J, Seemann U et al. Die direkten und indirekten Kosten der Schizophrenie. Fortschr Neurol Psychiat 1999; 67: 29-36
9. Lauterbach KW, Schrappe M (Hrsg). Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine. Stuttgart: Schattauer, 2001
10. Laux G. Kosten-Nutzen-Analyse neuerer versus älterer Antidepressiya. Klinik & Forschung 1999; 5 (S6): 1-12
11. Laux G. Cost-benefit analysis of newer versus older antidepressants. Pharmacopsychiatry 2001; 34: 1-5
12. McCombs JS, Nichol MB, Johnstone BM et al. Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatr Serv 2000; 51: 1630-1638
13. Müller-Bohn T, Ulrich V. Pharmakoökonomie. Einführung in die ökonomische Analyse der Arzneimittelanwendung. Stuttgart: Wiss Verlagsges, 2000
14. Procyshyn RM, Thompson D, Tse G. Pharmacoeconomics of clozapine, risperidone and olanzapine: A review of the literature. CNS Drugs 2000; 13: 47-76
15. Revicki D, Brown R, Keller M et al. Cost-effectiveness of newer anti-depressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47-58
16. Rössler W, Salize J, Knapp M. Die Kosten der Schizophrenie. Fortschr Neurol Psychiat 1998; 66: 496-504
17. Graf von der Schulenburg M, Über A, Höffler J et al. Untersuchungen zu den direkten und indirekten Kosten der Schizophrenie - Eine empirische Analyse. Gesundh ökon Qual manag 1998; 3: 214-226
18. Schütz C, Laux G, Günther W. Kosten-Nutzen-Analysen "atypischer" Neuroleptika. Pharmakoökonomische Modellrechnungen und Vergleichsstudien neuerer "atypischer" versus konventionelle Neuroleptika. Psychopharmakotherapie 2001; 8: 138-143
19. Stewart A. Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord 1998; 48: 257-263
20. Woods S, Rizzo J. Cost-effectiveness of antidepressant treatment reassessed. Brit J Psychiatry 1997; 170: 257-263
21. Zito J. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatr Clin North Am 1998; 21: 181-202